Is TEE the key for novel antibiotics?

  30 September 2022

Research suggests a Transferable Exclusivity Extension (TEE) system is “the only existing option capable of incentivising antibiotic R&D in a sustainable manner” for Europe.

According to a new report, implementing a Transferable Exclusivity Extension (TEE) system could solve the “broken economic model” for researching and developing new antibiotics in Europe.

As the threat of antimicrobial resistance (AMR), sometimes called the hidden or silent pandemic, grows, new and novel antibiotics are needed to combat infections becoming more resistant to current treatments.

Research published by Charles River Associates for The European Federation of Pharmaceutical Industries and Associations (EFPIA) suggests adopting a TEE proposal is the most credible and workable solution for driving antibiotic research in Europe. The authors suggest under such a system, two new antibiotics a year could be brought to patients over the next decade, preventing some of the 400,000 deaths associated with AMR every year in the EU.

Download the report

Author(s): European Pharmaceutical Review
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed